+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug Delivery Across Blood Brain Barrier Market - Global Forecast to 2030- Product Image
Drug Delivery Across Blood Brain Barrier Market - Global Forecast to 2030- Product Image
Sale

Drug Delivery Across Blood Brain Barrier Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337118
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Delivery Across Blood Brain Barrier Market grew from USD 726.97 million in 2024 to USD 796.26 million in 2025. It is expected to continue growing at a CAGR of 9.09%, reaching USD 1.22 billion by 2030.

The unparalleled complexity of the blood-brain barrier presents both a formidable obstacle and a unique opportunity for delivering therapeutics to the central nervous system. As neurological and oncological disorders continue to exact significant human and economic tolls, the imperative to develop safe, efficient, and targeted delivery mechanisms has never been greater. This executive summary distills the key drivers, obstacles, and innovations defining the contemporary landscape of drug delivery across the blood-brain barrier. It outlines emerging scientific breakthroughs, regulatory shifts, and commercial considerations, all of which converge to shape the strategic imperatives for stakeholders in pharmaceutical development, medical device engineering, and clinical research. By synthesizing insights from multiple segmentation frameworks, highlighting the geopolitical and tariff-driven influences of 2025, and profiling the leading organizations driving progress, this summary equips decision-makers with the intelligence needed to calibrate R&D priorities, investment strategies, and collaborative partnerships. Moreover, actionable recommendations offer a roadmap for accelerating translational pathways, optimizing supply chains, and maximizing therapeutic impact. This introduction lays the groundwork for a deeper exploration of transformative trends and market dynamics in the following sections.

Transformative Shifts Reshaping the Blood-Brain Barrier Delivery Landscape

Over the past decade, scientific breakthroughs have redefined what is possible in crossing the blood-brain barrier. Innovations such as lipid nanoparticle formulations originally developed for mRNA vaccines have been repurposed to ferry small molecules and biologics into the central nervous system with unprecedented precision. Meanwhile, viral vectors and monoclonal antibody strategies have transitioned from proof-of-concept to late-stage clinical evaluation, spurred by advances in vector engineering and targeted ligand design. Regulatory bodies have responded by crafting adaptive pathways for high-unmet-need indications, enabling expedited review for intrathecal and intranasal modalities. The convergence of big data analytics, in silico modeling, and high-throughput screening has further accelerated candidate selection and safety profiling. Simultaneously, strategic partnerships between biotech startups and established pharmaceutical companies have flourished, leveraging complementary expertise in delivery platforms and therapeutic pipelines. These transformative shifts are collectively lowering barriers to market entry, enhancing clinical success rates, and expanding the therapeutic horizon to include complex neurodegenerative and genetic disorders that were once deemed intractable.

Assessing the Cumulative Impact of United States Tariffs in 2025

In 2025, newly imposed United States tariffs on critical raw materials and specialized equipment have exerted measurable pressure on supply chains vital to drug delivery innovation. Tariffs on pharmaceutical excipients used in lipid nanoparticle synthesis have increased production costs by up to 8 percent, while levies on advanced polymer precursors have constrained capacity expansions for polymeric nanoparticles. Equipment required for aseptic intrathecal manufacturing has similarly faced import surcharges, prompting select CDMOs to relocate portions of their operations to tariff-exempt zones. Research institutions dependent on imported viral vector production reagents have reported delays, exacerbating timelines for pre-clinical and clinical programs. Although some cost pressures are being mitigated through local sourcing initiatives and tariff exclusion petitions, the cumulative burden has shifted strategic sourcing decisions and forced companies to reevaluate their global manufacturing footprints. As a consequence, licensing agreements and co-development partnerships that deliver onshore production capabilities are emerging as key competitive differentiators.

Key Segmentation Insights into Drug Delivery Approaches

This analysis draws on five complementary segmentation frameworks to illuminate nuanced opportunity spaces. When viewed through drug type, the portfolio spans biologics and large molecules including peptides and proteins, lipid and polymeric nanoparticles, traditional small molecules, and viral vectors such as adenoviral and lentiviral systems. Delivery method segmentation encompasses intranasal approaches employing inhalation or spray, intrathecal administration, intravenous infusion, and orthotopic direct injection via cranial or stereotactic surgery. Therapeutic application segmentations reveal distinct trajectories in targeting genetic disorders like metachromatic leukodystrophy and phenylketonuria, neurodegenerative conditions including Alzheimer’s and Parkinson’s diseases, and oncology indications such as glioblastoma and medulloblastoma. Carrier systems vary from liposomal and polymeric dendrimer or polymersome formulations to monoclonal antibody platforms incorporating antibody-drug conjugates. Finally, development stage segmentation distinguishes pre-clinical research, clinical trials across Phase I, II, and III, post-marketing surveillance, and ongoing research and development endeavors. Integrating insights across these dimensions uncovers high-value niches-such as lipid nanoparticle delivery of siRNA for neurodegenerative targets in mid-stage clinical trials-and highlights where unmet needs and competitive intensity intersect.

Essential Regional Insights Driving Market Dynamics

Geographic dynamics shape both opportunity and risk in this market. In the Americas, robust venture capital flows and favorable regulatory frameworks have fostered a dense ecosystem of biotech innovators specializing in intrathecal therapies and monoclonal antibody conjugates. Meanwhile, Europe, Middle East & Africa present a diverse patchwork of reimbursement policies, with leading academic centers in Western Europe pioneering novel nanoparticle formulations and gene therapy vectors. Access constraints in certain EMEA regions, however, underscore the need for adaptive pricing strategies and regional manufacturing alliances. In Asia-Pacific, government-led initiatives in China, Japan, and South Korea are accelerating clinical development of viral vector and lipid nanoparticle platforms, supported by significant infrastructure investments and streamlined clinical trial approvals. Cross-regional partnerships are proliferating, allowing companies to leverage localized production, regulatory harmonization efforts, and patient access programs to optimize global launch plans.

Prominent Companies and Their Role in Advancing Delivery Technologies

Market leadership and innovation are propelled by a diverse array of organizations. Established conglomerates such as Pfizer Inc. and F. Hoffmann-La Roche Ltd. continue to invest heavily in lipid nanoparticle and monoclonal antibody conjugate research, leveraging their global scale and manufacturing capacity. Biotech pioneers including Bioasis Technologies Inc., Angiochem Inc., and Ossianix, Inc. are advancing targeted delivery platforms for neurodegenerative and genetic disorders. Pharmaceutical specialists like AbbVie Inc. and Bristol-Myers Squibb Company are pursuing viral vector and polymeric carrier collaborations to expand their central nervous system pipelines. Specialty innovators-Nanoform Finland Oyj, Carthera S.A., and CNS Pharmaceuticals, Inc.-are refining nanoparticle characteristics and intracranial infusion techniques. Contract service providers such as ICON PLC and Cordance Medical Inc. are scaling aseptic delivery manufacturing, while academic spin-outs and research partners like JCR Pharmaceuticals Co., Ltd. and Boehringer Ingelheim International GmbH are translating pre-clinical breakthroughs into clinical candidates. Lastly, 3M Company’s material science expertise underpins next-generation excipient design, ensuring the reproducibility and safety of emerging delivery vehicles.

Actionable Recommendations for Industry Leaders

To capitalize on shifting market dynamics, industry leaders should align R&D investments with the most promising delivery modalities and therapeutic indications. Prioritize partnerships that secure onshore manufacturing of critical raw materials and equipment to mitigate tariff exposures. Advance platform technologies-particularly lipid nanoparticles and targeted viral vectors-through adaptive clinical trial designs that leverage real-world evidence to accelerate regulatory approvals. Foster cross-disciplinary collaborations between material scientists, immunologists, and clinical neurologists to enhance translational fidelity. Leverage regional strengths by co-developing trials in geographies with expedited approval pathways while deploying tiered pricing and local production models to ensure broad patient access. Finally, invest in digital and supply chain analytics to optimize batch release timelines, traceability, and quality assurance, thereby reducing time to market and reinforcing competitive advantage.

Conclusion: Charting the Future of Central Nervous System Therapeutics

The imperative to overcome the blood-brain barrier has catalyzed a wave of scientific and commercial innovation. By integrating advanced carrier systems, precise delivery methods, and strategic geographic planning, organizations can unlock transformative therapeutic benefits for patients with unmet central nervous system needs. The interplay of newly imposed tariffs, shifting regulatory landscapes, and burgeoning regional ecosystems underscores the importance of agility and foresight. As technology platforms mature and development pipelines expand into more complex indications, stakeholders equipped with deep segmentation insights and knowledge of key players will be best positioned to accelerate translational success. This conclusion reaffirms the critical role of collaborative partnerships, evidence-driven investment, and operational resilience in charting a sustainable growth trajectory for drug delivery across the blood-brain barrier.

Market Segmentation & Coverage

This research report categorizes the Drug Delivery Across Blood Brain Barrier Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics & Large Molecules
    • Peptides
    • Proteins
  • Nanoparticles
    • Lipid Nanoparticles
    • Polymeric Nanoparticles
  • Small Molecules
  • Viral Vectors
    • Adenoviral Vectors
    • Lentiviral Vectors
  • Intranasal
    • Inhalation
    • Spray
  • Intrathecal
  • Intravenous
  • Orthotopic Direct Injection
    • Cranial Injection
    • Stereotactic Surgery
  • Genetic Disorders
    • Metachromatic Leukodystrophy
    • Phenylketonuria
  • Neurodegenerative Disorders
    • Alzheimer's Disease
    • Parkinson's Disease
  • Oncology
    • Glioblastoma
    • Medulloblastoma
  • Liposomal Carriers
  • Monoclonal Antibodies
    • Antibody-Drug Conjugates
  • Polymeric Carriers
    • Dendrimers
    • Polymersomes
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
  • Post-Marketing
  • Pre-Clinical
  • Research & Development

This research report categorizes the Drug Delivery Across Blood Brain Barrier Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drug Delivery Across Blood Brain Barrier Market to delves into recent significant developments and analyze trends in each of the following companies:

  • 3M Company
  • AbbVie Inc.
  • Angiochem Inc.
  • Bioasis Technologies Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Carthera S.A.
  • CNS Pharmaceuticals, Inc.
  • Cordance Medical Inc.
  • F. Hoffmann-La Roche Ltd.
  • ICON PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Nanoform Finland Oyj
  • Ossianix, Inc.
  • Pfizer Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Delivery Across Blood Brain Barrier Market, by Drug Type
8.1. Introduction
8.2. Biologics & Large Molecules
8.2.1. Peptides
8.2.2. Proteins
8.3. Nanoparticles
8.3.1. Lipid Nanoparticles
8.3.2. Polymeric Nanoparticles
8.4. Small Molecules
8.5. Viral Vectors
8.5.1. Adenoviral Vectors
8.5.2. Lentiviral Vectors
9. Drug Delivery Across Blood Brain Barrier Market, by Delivery Method
9.1. Introduction
9.2. Intranasal
9.2.1. Inhalation
9.2.2. Spray
9.3. Intrathecal
9.4. Intravenous
9.5. Orthotopic Direct Injection
9.5.1. Cranial Injection
9.5.2. Stereotactic Surgery
10. Drug Delivery Across Blood Brain Barrier Market, by Therapeutic Application
10.1. Introduction
10.2. Genetic Disorders
10.2.1. Metachromatic Leukodystrophy
10.2.2. Phenylketonuria
10.3. Neurodegenerative Disorders
10.3.1. Alzheimer's Disease
10.3.2. Parkinson's Disease
10.4. Oncology
10.4.1. Glioblastoma
10.4.2. Medulloblastoma
11. Drug Delivery Across Blood Brain Barrier Market, by Carrier Systems
11.1. Introduction
11.2. Liposomal Carriers
11.3. Monoclonal Antibodies
11.3.1. Antibody-Drug Conjugates
11.4. Polymeric Carriers
11.4.1. Dendrimers
11.4.2. Polymersomes
12. Drug Delivery Across Blood Brain Barrier Market, by Development Stage
12.1. Introduction
12.2. Clinical Trials
12.2.1. Phase I
12.2.2. Phase II
12.2.3. Phase III
12.3. Post-Marketing
12.4. Pre-Clinical
12.5. Research & Development
13. Americas Drug Delivery Across Blood Brain Barrier Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Drug Delivery Across Blood Brain Barrier Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Drug Delivery Across Blood Brain Barrier Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. 3M Company
16.3.2. AbbVie Inc.
16.3.3. Angiochem Inc.
16.3.4. Bioasis Technologies Inc.
16.3.5. Boehringer Ingelheim International GmbH
16.3.6. Bristol-Myers Squibb Company
16.3.7. Carthera S.A.
16.3.8. CNS Pharmaceuticals, Inc.
16.3.9. Cordance Medical Inc.
16.3.10. F. Hoffmann-La Roche Ltd.
16.3.11. ICON PLC
16.3.12. JCR Pharmaceuticals Co., Ltd.
16.3.13. Nanoform Finland Oyj
16.3.14. Ossianix, Inc.
16.3.15. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET MULTI-CURRENCY
FIGURE 2. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET MULTI-LANGUAGE
FIGURE 3. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CRANIAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHENYLKETONURIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY LIPOSOMAL CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POST-MARKETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 111. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 113. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 114. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 115. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 116. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 117. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 118. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 120. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 121. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 122. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 125. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 126. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 193. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 195. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 196. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 197. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 198. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 199. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 200. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 203. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 204. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 205. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 206. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 207. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 208. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 209. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 211. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 212. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 213. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 214. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 215. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 216. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 218. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 219. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 220. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 221. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 223. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 224. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 241. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 243. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 244. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 246. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 247. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 248. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 250. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 251. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 252. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 253. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 254. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES DR

Companies Mentioned

  • 3M Company
  • AbbVie Inc.
  • Angiochem Inc.
  • Bioasis Technologies Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Carthera S.A.
  • CNS Pharmaceuticals, Inc.
  • Cordance Medical Inc.
  • F. Hoffmann-La Roche Ltd.
  • ICON PLC
  • JCR Pharmaceuticals Co., Ltd.
  • Nanoform Finland Oyj
  • Ossianix, Inc.
  • Pfizer Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions - Product Image

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions

  • Report
  • 375 Pages
  • Global
From
Drug Delivery Across Blood Brain Barrier Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Drug Delivery Across Blood Brain Barrier Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Drug Delivery Across Blood Brain Barriers - Global Strategic Business Report - Product Image

Drug Delivery Across Blood Brain Barriers - Global Strategic Business Report

  • Report
  • 297 Pages
  • Global
From
Blood Brain Barrier Technologies Market Report 2025 - Product Image

Blood Brain Barrier Technologies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors - Product Image

Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors

  • Book

About the Blood Brain Barrier Drug Delivery Market

The Blood Brain Barrier Drug Delivery market is a subset of the larger Drug Delivery market. It focuses on the development of drugs that can cross the blood-brain barrier, a protective layer of cells that separates the brain from the rest of the body. These drugs are used to treat neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. The Blood Brain Barrier Drug Delivery market is highly competitive, with companies investing heavily in research and development to create new drugs and delivery systems. The market is driven by the increasing prevalence of neurological diseases, as well as the need for more effective treatments. Additionally, advances in technology have enabled the development of more efficient drug delivery systems. Some companies in the Blood Brain Barrier Drug Delivery market include AbbVie, AstraZeneca, Biogen, Eli Lilly, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.